Skip to main content

Advertisement

SpringerLink
Log in

Preoperative Selection and Optimization for Liver Resection in Colorectal Cancer Liver Metastases

  • Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)
  • Published:
Current Colorectal Cancer Reports

Abstract

Purpose of Review

Colorectal cancer is the third most common cancer in incidence and the leading cause of death among males and females. Colorectal cancer liver metastatic disease (CRCLM) is the most common cause of death in these patients. Liver resection is the best treatment modality to be offered for CRCLM patients; however, most patients are not good candidates for liver resection. The scope of this review is to discuss the preoperative selection process and the optimization methods that can be used to maximize the eligibility for liver resection in CRCLM.

Recent Findings

The advancement in perioperative management and the engagement of the multidisciplinary methodology in treating patients with colorectal liver metastasis resulted in improving the survival rates, decreasing perioperative complications, and expanding the criteria for liver resection for CRCLM patients.

Summary

The management of colorectal cancer liver metastasis is evolving. Patient selection and perioperative optimization play an essential role to offer a safer liver resection with a reasonable oncologic outcome; personalization of therapy is the next evolution in treating CRCLM patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    Article  PubMed  Google Scholar 

  2. •• Network NCC. Colon Cancer (Version 1.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed 25 Feb 2018. The recent edition of NCCN Clinical cancer guideline for management of all stages of colon cancer including colon cancer liver metastasis.

  3. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer. 2006;42(14):2212–21.

    Article  PubMed  Google Scholar 

  4. Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol. 2007;14(2):766–70.

    Article  PubMed  Google Scholar 

  5. Hur H, Ko YT, Min BS, Kim KS, Choi JS, Sohn SK, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197(6):728–36.

    Article  PubMed  Google Scholar 

  6. Lee WS, Yun SH, Chun HK, Lee WY, Kim SJ, Choi SH, et al. Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol. 2008;42(8):945–9.

    Article  PubMed  Google Scholar 

  7. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.

    PubMed  PubMed Central  Google Scholar 

  8. Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141(5):460–6. discussion 466-467

    Article  PubMed  Google Scholar 

  9. Balzan S, Nagarajan G, Farges O, Galleano CZ, Dokmak S, Paugam C, et al. Safety of liver resections in obese and overweight patients. World J Surg. 2010;34(12):2960–8.

    Article  PubMed  Google Scholar 

  10. Pulitano C, Crawford M, Joseph D, Aldrighetti L, Sandroussi C. Preoperative assessment of postoperative liver function: the importance of residual liver volume. J Surg Oncol. 2014;110(4):445–50.

    Article  PubMed  Google Scholar 

  11. van den Broek MA, Olde Damink SW, Dejong CH, et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int. 2008;28(6):767–80.

    Article  PubMed  CAS  Google Scholar 

  12. Guglielmi A, Ruzzenente A, Conci S, Valdegamberi A, Iacono C. How much remnant is enough in liver resection? Dig Surg. 2012;29(1):6–17.

    Article  PubMed  Google Scholar 

  13. Little SA, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg. 2002;6(1):88–94.

    Article  PubMed  Google Scholar 

  14. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg. 1998;2(3):292–8.

    Article  PubMed  CAS  Google Scholar 

  15. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000;191(1):38–46.

    Article  PubMed  CAS  Google Scholar 

  16. de Meijer VE, Kalish BT, Puder M, Ijzermans JN. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg. 2010;97(9):1331–9.

    Article  PubMed  Google Scholar 

  17. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci. 2005;329(3):111–6.

    Article  PubMed  Google Scholar 

  18. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.

    Article  PubMed  Google Scholar 

  19. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28(4):629–36.

    Article  PubMed  CAS  Google Scholar 

  20. Agrawal S, Daruwala C. Metabolic syndrome and hepatic resection: improving outcome. HPB (Oxford). 2011;13(12):846–59.

    Article  Google Scholar 

  21. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92(2):399–404.

    Article  PubMed  CAS  Google Scholar 

  22. Kang H, Greenson JK, Omo JT, Chao C, Peterman D, Anderson L, et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol. 2006;101(10):2247–53.

    Article  PubMed  CAS  Google Scholar 

  23. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.

    Article  PubMed  Google Scholar 

  24. Vetelainen R, van Vliet A, Gouma DJ, van Gulik TM. Steatosis as a risk factor in liver surgery. Ann Surg. 2007;245(1):20–30.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gallagher-Allred CR, Voss AC, Finn SC, McCamish MA. Malnutrition and clinical outcomes: the case for medical nutrition therapy. J Am Diet Assoc. 1996;96(4):361–6. 369; quiz 367-368

    Article  PubMed  CAS  Google Scholar 

  26. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc. 2016;75(2):188–98.

    Article  PubMed  CAS  Google Scholar 

  27. Tsai S. Importance of lean body mass in the oncologic patient. Nutr Clin Pract. 2012;27(5):593–8.

    Article  PubMed  Google Scholar 

  28. Bardou M, Barkun AN, Martel M. Republished: obesity and colorectal cancer. Postgrad Med J. 2013;89(1055):519–33.

    Article  PubMed  CAS  Google Scholar 

  29. Hamady ZZ, Rees M, Welsh FK, et al. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases. Br J Surg. 2013;100(6):820–6.

    Article  PubMed  CAS  Google Scholar 

  30. Pathak S, Pandanaboyana S, Daniels I, Smart N, Prasad KR. Obesity and colorectal liver metastases: mechanisms and management. Surg Oncol. 2016;25(3):246–51.

    Article  PubMed  Google Scholar 

  31. Evans DC, Martindale RG, Kiraly LN, Jones CM. Nutrition optimization prior to surgery. Nutr Clin Pract. 2014;29(1):10–21.

    Article  PubMed  Google Scholar 

  32. Sungurtekin H, Sungurtekin U, Balci C, Zencir M, Erdem E. The influence of nutritional status on complications after major intraabdominal surgery. J Am Coll Nutr. 2004;23(3):227–32.

    Article  PubMed  Google Scholar 

  33. • Rinella ME, Alonso E, Rao S, Whitington P, Fryer J, Abecassis M, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transplant. 2001;7(5):409–14. The recent edition of American Association for the Study of Liver Diseases (AASLD) for management of NAFLD.

    Article  CAS  Google Scholar 

  34. van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, ten Kate FJ, van Gulik TM, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010;256(1):159–68.

    Article  PubMed  Google Scholar 

  35. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.

    Article  PubMed  Google Scholar 

  36. Weimann A, Braga M, Carli F, Higashiguchi T, Hübner M, Klek S, et al. ESPEN guideline: clinical nutrition in surgery. Clin Nutr. 2017;36(3):623–50.

    Article  PubMed  Google Scholar 

  37. Melloul E, Hubner M, Scott M, et al. Guidelines for perioperative care for liver surgery: Enhanced Recovery After Surgery (ERAS) society recommendations. World J Surg. 2016;40(10):2425–40.

    Article  PubMed  Google Scholar 

  38. Gong Y, Liu Z, Liao Y, Mai C, Chen T, Tang H, et al. Effectiveness of omega-3 polyunsaturated fatty acids based lipid emulsions for treatment of patients after hepatectomy: a prospective clinical trial. Nutrients. 2016;8(6):357.

    Article  PubMed Central  CAS  Google Scholar 

  39. Ibrahim ES, Saleh SM, El Hoseeny M, El shaarawy A. Effect of omega-3 on hepatic regeneration in adult living donors undergoing hepatic resections for liver transplantation: a randomized controlled trial. J Crit Care. 2016;31(1):157–62.

    Article  PubMed  CAS  Google Scholar 

  40. Zhang B, Wei G, Li R, Wang Y, Yu J, Wang R, et al. N-3 fatty acid-based parenteral nutrition improves postoperative recovery for cirrhotic patients with liver cancer: a randomized controlled clinical trial. Clin Nutr. 2017;36(5):1239–44.

    Article  PubMed  CAS  Google Scholar 

  41. Zhang C, Chen B, Jiao A, Li F, Wang B, Sun N, et al. The benefit of immunonutrition in patients undergoing hepatectomy: a systematic review and meta-analysis. Oncotarget. 2017;8(49):86843–52.

    PubMed  PubMed Central  Google Scholar 

  42. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand. 1986;220(1):83–8.

    Article  PubMed  CAS  Google Scholar 

  43. Chen TY, Chen CL, Tsang LL, et al. Correlation between hepatic steatosis, hepatic volume, and spleen volume in live liver donors. Transplant Proc. 2008;40(8):2481–3.

    Article  PubMed  Google Scholar 

  44. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27(1):103–7.

    Article  PubMed  CAS  Google Scholar 

  45. Wang CL, Liang L, Fu JF, Zou CC, Hong F, Xue JZ, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol. 2008;14(10):1598–602.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Reeves JG, Suriawinata AA, Ng DP, Holubar SD, Mills JB, Barth RJ Jr. Short-term preoperative diet modification reduces steatosis and blood loss in patients undergoing liver resection. Surgery. 2013;154(5):1031–7.

    Article  PubMed  Google Scholar 

  47. Stadler M, Nuyens V, Seidel L, Albert A, Boogaerts JG. Effect of nutritional status on oxidative stress in an ex vivo perfused rat liver. Anesthesiology. 2005;103(5):978–86.

    Article  PubMed  Google Scholar 

  48. Hassanain M, Metrakos P, Fisette A, Doi SAR, Schricker T, Lattermann R, et al. Randomized clinical trial of the impact of insulin therapy on liver function in patients undergoing major liver resection. Br J Surg. 2013;100(5):610–8.

    Article  PubMed  CAS  Google Scholar 

  49. Eshuis WJ, Hermanides J, van Dalen JW, van Samkar G, Busch ORC, van Gulik TM, et al. Early postoperative hyperglycemia is associated with postoperative complications after pancreatoduodenectomy. Ann Surg. 2011;253(4):739–44.

    Article  PubMed  Google Scholar 

  50. Jackson RS, Amdur RL, White JC, Macsata RA. Hyperglycemia is associated with increased risk of morbidity and mortality after colectomy for cancer. J Am Coll Surg. 2012;214(1):68–80.

    Article  PubMed  Google Scholar 

  51. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003;7(1):109–17.

    Article  PubMed  Google Scholar 

  52. Sugihara K, Uetake H. Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. J Hepatobiliary Pancreat Sci. 2012;19(5):523–7.

    Article  PubMed  Google Scholar 

  53. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010;14(11):1691–700.

    Article  PubMed  Google Scholar 

  54. Khoo E, O'Neill S, Brown E, Wigmore SJ, Harrison EM. Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases. HPB (Oxford). 2016;18(6):485–93.

    Article  Google Scholar 

  55. Araujo RL, Gonen M, Herman P. Chemotherapy for patients with colorectal liver metastases who underwent curative resection improves long-term outcomes: systematic review and meta-analysis. Ann Surg Oncol. 2015;22(9):3070–8.

    Article  PubMed  Google Scholar 

  56. Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, et al. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep. 2012;27(6):1849–56.

    PubMed  CAS  Google Scholar 

  57. Wang ZM, Chen YY, Chen FF, Wang SY, Xiong B. Peri-operative chemotherapy for patients with resectable colorectal hepatic metastasis: a meta-analysis. Eur J Surg Oncol. 2015;41(9):1197–203.

    Article  PubMed  Google Scholar 

  58. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15.

    Article  PubMed  CAS  Google Scholar 

  59. •• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. The recent edition of ESMO Clinical cancer guideline for management of metastatic colon cancer including liver metastasis.

    Article  PubMed  Google Scholar 

  60. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18. discussion 318-321

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23(9):2038–48.

    Article  PubMed  CAS  Google Scholar 

  62. Adam R, Barroso E, Laurent C, Nuzzo G, Hubert C, Mentha G, et al. Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases. J Clin Oncol. 2011;29(15):3519.

    Article  Google Scholar 

  63. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57. discussion 657-648

    PubMed  PubMed Central  Google Scholar 

  64. Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010;252(5):774–87.

    Article  PubMed  Google Scholar 

  65. Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20(6):985–92.

    Article  PubMed  CAS  Google Scholar 

  66. Nordlinger B, Van Cutsem E, Rougier P, et al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer. 2007;43(14):2037–45.

    Article  PubMed  CAS  Google Scholar 

  67. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16(8):1311–9.

    Article  PubMed  CAS  Google Scholar 

  68. Haraldsdottir S, Goldberg RM. Conversion therapy for initially borderline/unresectable metastases in colon cancer: what is the best neoadjuvant chemotherapy? Curr Colorect Cancer Rep. 2017;13(6):419–28.

    Article  Google Scholar 

  69. • Okuno M, Hatano E, Nishino H, Seo S, Taura K, Uemoto S. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: a systematic review. Eur J Surg Oncol. 2017;43(6):1003–12. This systematic review demonstrated similar result of correlation between response and conversion rate between chemotherapy without molecular target agents and with anti-EGFR agent.

    Article  PubMed  CAS  Google Scholar 

  70. Fong Y, Bentrem DJ. CASH (chemotherapy-associated steatohepatitis) costs. Ann Surg. 2006;243(1):8–9.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Maor Y, Malnick S. Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol. 2013;2013:815105.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Duwe G, Knitter S, Pesthy S, Beierle AS, Bahra M, Schmelzle M, et al. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. Eur J Surg Oncol. 2017;43(9):1668–81.

    Article  PubMed  CAS  Google Scholar 

  73. Zhao J, van Mierlo KMC, Gomez-Ramirez J, et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017;104(8):990–1002.

    Article  PubMed  CAS  Google Scholar 

  74. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet. 2008;371(9617):963–5.

    Article  PubMed  Google Scholar 

  76. Welsh FK, Tilney HS, Tekkis PP, John TG, Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96(7):1037–42.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–24.

    Article  PubMed  Google Scholar 

  78. White MA, Fong Y, Singh G. Chemotherapy-associated hepatotoxicities. Surg Clin North Am. 2016;96(2):207–17.

    Article  PubMed  Google Scholar 

  79. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24(13):2065–72.

    Article  PubMed  CAS  Google Scholar 

  80. Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17(10):1225–39.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Shindoh J, Truty MJ, Aloia TA, Curley SA, Zimmitti G, Huang SY, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg. 2013;216(2):201–9.

    Article  PubMed  Google Scholar 

  82. Ferrero A, Vigano L, Polastri R, et al. Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J Surg. 2007;31(8):1643–51.

    Article  PubMed  Google Scholar 

  83. Evrard S, Poston G, Kissmeyer-Nielsen P, Diallo A, Desolneux G, Brouste V, et al. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PLoS One. 2014;9(12):e114404.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. • Chan DL, Alzahrani NA, Morris DL, Chua TC. Systematic review and meta-analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases. Surg Oncol. 2015;24(3):162–71. This meta-analysis reviews demonstrated, hepatic arterial infusion chemotherapy in conjunction with current systemic chemotherapy may allow some patients with unresectable colorectal liver metastasis to undergo resection with potentially long-term survival.

    Article  PubMed  Google Scholar 

  85. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.

    Article  PubMed  Google Scholar 

  86. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol. 2003;10(9):1059–69.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Faitot F, Faron M, Adam R, Elias D, Cimino M, Cherqui D, et al. Two-stage hepatectomy versus 1-stage resection combined with radiofrequency for bilobar colorectal metastases: a case-matched analysis of surgical and oncological outcomes. Ann Surg. 2014;260(5):822–7. discussion 827-828

    Article  PubMed  Google Scholar 

  88. Abdalla EK. Commentary: radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology. Am J Surg. 2009;197(6):737–9.

    Article  PubMed  Google Scholar 

  89. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–8.

    PubMed  Google Scholar 

  90. Bozkurt MF, Salanci BV, Ugur O. Intra-arterial radionuclide therapies for liver tumors. Semin Nucl Med. 2016;46(4):324–39.

    Article  PubMed  Google Scholar 

  91. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology. 2013;58(6):2188–97.

    Article  PubMed  CAS  Google Scholar 

  92. Kiszkaa J, Karczmarek-Borowska B. Radioembolization treatment for liver metastases. Contemp Oncol. 2017;21(4):274–8.

    Google Scholar 

  93. Wright GP, Marsh JW, Varma MK, Doherty MG, Bartlett DL, Chung MH. Liver resection after selective internal radiation therapy with Yttrium-90 is safe and feasible: a bi-institutional analysis. Ann Surg Oncol. 2017;24(4):906–13.

    Article  PubMed  Google Scholar 

  94. Lewandowski RJ, Donahue L, Chokechanachaisakul A, Kulik L, Mouli S, Caicedo J, et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99–105.

    Article  PubMed  Google Scholar 

  95. Khan AS, Garcia-Aroz S, Ansari MA, Atiq SM, Senter-Zapata M, Fowler K, et al. Assessment and optimization of liver volume before major hepatic resection: current guidelines and a narrative review. Int J Surg. 2018;52:74–81.

    Article  PubMed  Google Scholar 

  96. Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.

    Article  PubMed  Google Scholar 

  97. Ironside N, Bell R, Bartlett A, McCall J, Powell J, Pandanaboyana S. Systematic review of perioperative and survival outcomes of liver resections with and without preoperative portal vein embolization for colorectal metastases. HPB (Oxford). 2017;19(7):559–66.

    Article  Google Scholar 

  98. Munene G, Parker RD, Larrigan J, Wong J, Sutherland F, Dixon E. Sequential preoperative hepatic vein embolization after portal vein embolization for extended left hepatectomy in colorectal liver metastases. World J Surg Oncol. 2013;11:134.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg. 2007;94(11):1386–94.

    Article  PubMed  CAS  Google Scholar 

  100. Thirunavukarasu P, Aloia TA. Preoperative assessment and optimization of the future liver remnant. Surg Clin North Am. 2016;96(2):197–205.

    Article  PubMed  Google Scholar 

  101. Abulkhir A, Limongelli P, Healey AJ, Damrah O, Tait P, Jackson J, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247(1):49–57.

    Article  PubMed  Google Scholar 

  102. Farges O, Belghiti J, Kianmanesh R, Marc Regimbeau J, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237(2):208–17.

    PubMed  PubMed Central  Google Scholar 

  103. Ethun CG, Maithel SK. Determination of resectability. Surg Clin North Am. 2016;96(2):163–81.

    Article  PubMed  Google Scholar 

  104. Hwang S, Lee SG, Ko GY, Kim BS, Sung KB, Kim MH, et al. Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy. Ann Surg. 2009;249(4):608–16.

    Article  PubMed  Google Scholar 

  105. Goere D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg. 2006;10(3):365–70.

    Article  PubMed  Google Scholar 

  106. Simoneau E, Alanazi R, Alshenaifi J, Molla N, Aljiffry M, Medkhali A, et al. Neoadjuvant chemotherapy does not impair liver regeneration following hepatectomy or portal vein embolization for colorectal cancer liver metastases. J Surg Oncol. 2016;113(4):449–55.

    Article  PubMed  Google Scholar 

  107. de Baere T, Teriitehau C, Deschamps F, Catherine L, Rao P, Hakime A, et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol. 2010;17(8):2081–9.

    Article  PubMed  Google Scholar 

  108. Isfordink CJ, Samim M, Braat M, et al. Portal vein ligation versus portal vein embolization for induction of hypertrophy of the future liver remnant: a systematic review and meta-analysis. Surg Oncol. 2017;26(3):257–67.

    Article  PubMed  CAS  Google Scholar 

  109. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg. 2000;232(6):777–85.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  110. Robles R, Marin C, Lopez-Conesa A, Capel A, Perez-Flores D, Parrilla P. Comparative study of right portal vein ligation versus embolisation for induction of hypertrophy in two-stage hepatectomy for multiple bilateral colorectal liver metastases. Eur J Surg Oncol. 2012;38(7):586–93.

    Article  PubMed  CAS  Google Scholar 

  111. Homayounfar K, Liersch T, Schuetze G, Niessner M, Goralczyk A, Meller J, et al. Two-stage hepatectomy (R0) with portal vein ligation—towards curing patients with extended bilobular colorectal liver metastases. Int J Color Dis. 2009;24(4):409–18.

    Article  CAS  Google Scholar 

  112. Lam VW, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford). 2013;15(7):483–91.

    Article  Google Scholar 

  113. Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veilhan LA, et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg. 2008;248(6):994–1005.

    Article  PubMed  Google Scholar 

  114. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255(3):405–14.

    Article  PubMed  Google Scholar 

  115. de Santibanes E, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: the “ALPPS” approach. Ann Surg. 2012;255(3):415–7.

    Article  PubMed  Google Scholar 

  116. Moris D, Ronnekleiv-Kelly S, Kostakis ID, Tsilimigras DI, Beal EW, Papalampros A, et al. Operative results and oncologic outcomes of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) versus two-stage hepatectomy (TSH) in patients with unresectable colorectal liver metastases: a systematic review and meta-analysis. World J Surg. 2018;42(3):806–15.

    Article  PubMed  Google Scholar 

  117. Eshmuminov D, Raptis DA, Linecker M, Wirsching A, Lesurtel M, Clavien PA. Meta-analysis of associating liver partition with portal vein ligation and portal vein occlusion for two-stage hepatectomy. Br J Surg. 2016;103(13):1768–82.

    Article  PubMed  CAS  Google Scholar 

  118. Oldhafer KJ, Stavrou GA, van Gulik TM, Core G. ALPPS—where do we stand, where do we go?: eight recommendations from the first international expert meeting. Ann Surg. 2016;263(5):839–41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, King Saud University, Riyadh, Saudi Arabia

    Ahmad Madkhali, Faisal Alalem, Abdulsalam Alsharaabi, Faisal Alsaif & Mazen Hassanain

  2. Department of Surgery, King Salman Hospital, Riyadh, Saudi Arabia

    Ghadeer Aljuhani

  3. Department of Oncology, McGill University, Montreal, Canada

    Mazen Hassanain

Authors
  1. Ahmad Madkhali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Faisal Alalem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ghadeer Aljuhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abdulsalam Alsharaabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Faisal Alsaif
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mazen Hassanain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mazen Hassanain.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Personalized Medicine in Colorectal Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Madkhali, A., Alalem, F., Aljuhani, G. et al. Preoperative Selection and Optimization for Liver Resection in Colorectal Cancer Liver Metastases. Curr Colorectal Cancer Rep 14, 89–97 (2018). https://doi.org/10.1007/s11888-018-0405-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-018-0405-x

Keywords

Search

Navigation